LAVAL, QB and ST. PAUL, Minn., June
8, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye
health business of Bausch Health Companies Inc. (NYSE/TSX: BHC)
("Bausch Health"), today announced that its affiliate has entered
into an agreement with Lochan LLC ("Lochan") to develop the
next-generation of Bausch + Lomb's eyeTELLIGENCE™
clinical decision support software. Using the existing cloud-based
infrastructure of eyeTELLIGENCE, this analytical software is being
designed to allow surgeons to seamlessly integrate all aspects of
the cataract, retinal and refractive surgery processes to maximize
their overall practice efficiency. The companies expect to launch
the initial phase of this next-generation software in 2022.
"Similar to what is being seen across the entire health care
spectrum, ophthalmologists are under tremendous pressure to find
ways to increase their efficiency and optimize workflow while
continuing to deliver the highest level of patient care. The need
for solutions that help them pursue this goal is massive," said
Joseph Gordon, U.S. president,
Bausch + Lomb. "In 2018, we started our journey to deliver on this
need when we became the first company to connect the operating room
to the cloud using our eyeTELLIGENCE technology. The agreement with
Lochan propels us into the next phase of this journey to further
enhance surgeon's ability to improve practice efficiency."
Ophthalmic surgical procedures require a sophisticated,
multi-step process that involves patient diagnostics, clinical
treatment planning, surgery planning, post-op analysis and more.
Today, the transitions between each step require the manual
transfer of data, which can be time consuming and lead to
unintended human error. The next-generation
eyeTELLIGENCE™ software platform is being designed to
create opportunities to streamline this complex process, resulting
in a more seamless connection from pre surgery assessment to
treatment planning and execution to post surgery evaluation.
"As a practicing surgeon, I have experienced first-hand the
disconnect that exists between the different phases of the surgical
planning process and the lack of interconnectivity between
technologies that we use," said Mark Lobanoff, M.D., director of refractive
surgery, North Suburban Eye Specialists, Minneapolis, MN, and founder, Lochan
LLC. "Just as Bausch + Lomb introduced
eyeTELLIGENCE™ to help address these challenges, I
founded Lochan because I understood the benefits that digital
integration could bring. That's why I believe that together, we
will be able to bring the capabilities of eyeTELLIGENCE™
to the next level -- helping surgeons use data to make more
informed and faster procedural and treatment decisions."
About eyeTELLIGENCE™ Platform
In 2018,
Bausch + Lomb launched the eyeTELLIGENCE™ cloud-based
digital platform as a way to help surgeons work smarter and find
new ways to use data to maximize their overall practice efficiency.
Today, eyeTELLIGENCE™, which is exclusively available on
the Stellaris Elite™ vision enhancement system, is used
by surgeons across the United
States.
About Lochan
Lochan is a software development company
focused on using advanced analytics and artificial intelligence to
bring novel solutions to complex ophthalmic calculations. Lochan
specializes in bringing sui generis approaches to create
cloud-based software platforms that are both unique and paradigm
shifting. Our goal is to give each surgeon the most accurate and
powerful software tools in the world while simultaneously making
them simple to use and effortlessly efficient. Visit
https://lochan.mn/ for more information.
About Bausch + Lomb
Bausch + Lomb, a leading global
eye health business of Bausch Health Companies Inc., is solely
focused on helping people see better to live better. Its core
businesses include over-the-counter products, dietary supplements,
eye care products, ophthalmic pharmaceuticals, contact lenses, lens
care products, ophthalmic surgical devices and instruments. Bausch
+ Lomb develops, manufactures and markets one of the most
comprehensive product portfolios in the industry, which is
available in approximately 100 countries. For more information,
visit www.bausch.com.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. For more information, visit
www.bauschhealth.com and connect with us on Twitter and
LinkedIn.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words
"anticipates," "expects," "intends," "plans," "should," "could," "would," "may,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, the risks and uncertainties discussed in Bausch
Health's most recent annual report on Form 10-K and detailed from
time to time in Bausch Health's other filings with the U.S.
Securities and Exchange Commission and the Canadian Securities
Administrators, which factors are incorporated herein by reference.
They also include, but are not limited to, risks and uncertainties
caused by or relating to the evolving COVID-19 pandemic, and the
fear of that pandemic and its potential effects, the severity,
duration and future impact of which are highly uncertain and cannot
be predicted, and which may have a material adverse impact on
Bausch Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
®/TM are trademarks of Bausch & Lomb
Incorporated or its affiliates.
Any other product/brand names and/or logos are trademarks of the
respective owners.
© 2021 Bausch & Lomb Incorporated or its affiliates.
ETG.0015.USA.21
Lochan Media
Contact:
|
Bausch Health
Investor Contact:
|
Mark
Lobanoff
|
Arthur
Shannon
|
mlobanoff@ovoeye.com
|
arthur.shannon@bauschhealth.com
|
(763)
772-7173
|
(514)
865-3855
|
|
(877) 281-6642 (toll
free)
|
|
|
|
Bausch Health
Media Contact:
|
|
Lainie
Keller
|
|
lainie.keller@bauschhealth.com
|
|
(908)
927-1198
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-and-lochan-enter-into-agreement-to-develop-the-next-generation-of-eyetelligence-clinical-decision-support-software-301307293.html
SOURCE Bausch Health Companies Inc.